April 2025

FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of patients with non-alcoholic fatty liver disease. GettyFat jabs can cut inflammation in two thirds of patients with non-alcoholic fatty liver disease[/caption] Nonalcoholic Fatty Liver Disease (NAFLD) a buildup of fat in the liver […]

Researchers in Dallas want to know if the class of drugs, GIP/GLP-1 receptor agonists, might be a secret weapon in the fight against breast cancer.

Results from the ESSENCE Phase III clinical trial published in the New England Journal of Medicine show treating patients with semaglutide can halt and even reverse liver disease.

WEDNESDAY, April 30, 2025 — Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1…

Although biologics are usually given by injection or intravenous infusion, oral formulations might be possible. In general, oral drugs offer many benefits, from simplified distribution to overall cost reductions for patients, as well as being easier use and often have better patient compliance. Nonetheless, acids and enzymes in the stomach can degrade biologics even before

GLP-1 weight loss treatment can be pricey. But employers who cover the treatments could end up saving on employee medical expenses overall. The finding is according to a new analysis of health insurance claims by global professional services firm, Aon, released Wednesday. The report looked at data for more than 50 million commercially insured people

submitted by /u/bevatsulfieten [link] [comments]

Covering the cost of pricey GLP-1 weight loss drugs could pay off for employers by cutting overall medical spending for people taking the medications, but not until year two, according to a massive analysis of health insurance claims by Aon released on Wednesday. Read more…

MONTREAL–(BUSINESS WIRE)–Innovaccer, the leading healthcare AI company, today announced that its recently acquired actuarial science company – Humbi AI, in collaboration with Landmark Science, Inc., will present a joint research at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 annual conference, scheduled to take place between May 13–16 in Montreal, QC, Canada.

Novo Nordisk strikes telehealth deals for obesity drug, following Eli Lilly  statnews.com Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%  CNBC Hims & Hers stock jumps on Novo Nordisk GLP-1 partnership  Yahoo Finance Why New Wegovy Deals Won’t Restore Novo Nordisk’s Obesity Lead  WSJ Novo Nordisk expands patient access to authentic, FDA-approved